{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:20:49Z","timestamp":1790198449107,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA193609-01A1"],"award-info":[{"award-number":["R01CA193609-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institue of Health","award":["1R21CA216585-01A1"],"award-info":[{"award-number":["1R21CA216585-01A1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13046-018-0906-0","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T18:06:29Z","timestamp":1537553189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGF\u03b2 pathway"],"prefix":"10.1186","volume":"37","author":[{"given":"Baojin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemichi","family":"Watari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence M","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"issue":"1","key":"906_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"906_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/cncr.30415","volume":"123","author":"JM Scalici","year":"2017","unstructured":"Scalici JM, Arapovic S, Saks EJ, Atkins KA, Petroni G, Duska LR, Slack-Davis JK. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Cancer. 2017;123(6):977\u201384.","journal-title":"Cancer"},{"key":"906_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.","journal-title":"Front Oncol"},{"issue":"9","key":"906_CR4","doi-asserted-by":"publisher","first-page":"11705","DOI":"10.3390\/ijms130911705","volume":"13","author":"K Nakayama","year":"2012","unstructured":"Nakayama K, Nakayama N, Katagiri H, Miyazaki K. Mechanisms of ovarian cancer metastasis: biochemical pathways. Int J Mol Sci. 2012;13(9):11705\u201317.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"906_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2009.09.017","volume":"291","author":"D Vergara","year":"2010","unstructured":"Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, Salzet M. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291(1):59\u201366.","journal-title":"Cancer Lett"},{"issue":"8","key":"906_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/gepi.21921","volume":"39","author":"EK Amankwah","year":"2015","unstructured":"Amankwah EK, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, et al. Epithelial-mesenchymal transition (EMT) gene variants and epithelial ovarian Cancer (EOC) risk. Genet Epidemiol. 2015;39(8):689\u201397.","journal-title":"Genet Epidemiol"},{"issue":"3","key":"906_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2174\/156800910791190175","volume":"10","author":"N Ahmed","year":"2010","unstructured":"Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 2010;10(3):268\u201378.","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"906_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ygyno.2010.01.010","volume":"117","author":"J Helleman","year":"2010","unstructured":"Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol. 2010;117(2):170\u20136.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"906_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/IGC.0b013e3181aaa93a","volume":"19","author":"S Yoshida","year":"2009","unstructured":"Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H, Kobayashi H. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer. 2009;19(6):992\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"906_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1757-2215-7-76","volume":"7","author":"M Takai","year":"2014","unstructured":"Takai M, Terai Y, Kawaguchi H, Ashihara K, Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M, et al. The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer. J Ovarian Res. 2014;7:76.","journal-title":"J Ovarian Res"},{"issue":"6","key":"906_CR11","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.stemcr.2016.11.001","volume":"7","author":"MV Bogachek","year":"2016","unstructured":"Bogachek MV, Park JM, De Andrade JP, Lorenzen AW, Kulak MV, White JR, Gu VW, Wu VT, Weigel RJ. Inhibiting the SUMO pathway represses the Cancer stem cell population in breast and colorectal carcinomas. Stem Cell Reports. 2016;7(6):1140\u201351.","journal-title":"Stem Cell Reports"},{"key":"906_CR12","doi-asserted-by":"crossref","unstructured":"Bocci F, Jolly MK, Tripathi SC, Aguilar M, Hanash SM, Levine H, Onuchic JN. Numb prevents a complete epithelial\u2013mesenchymal transition by modulating Notch signalling. J R Soc Interface. 2017;14:20170512.","DOI":"10.1098\/rsif.2017.0512"},{"issue":"23","key":"906_CR13","doi-asserted-by":"publisher","first-page":"12203","DOI":"10.18632\/oncotarget.2622","volume":"5","author":"LA Baldwin","year":"2014","unstructured":"Baldwin LA, Hoff JT, Lefringhouse J, Zhang M, Jia C, Liu Z, Erfani S, Jin H, Xu M, She QB, et al. CD151-alpha3beta1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget. 2014;5(23):12203\u201317.","journal-title":"Oncotarget"},{"issue":"3","key":"906_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ygyno.2013.09.034","volume":"131","author":"RC Arend","year":"2013","unstructured":"Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt\/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013;131(3):772\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"906_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/01635581.2014.853087","volume":"66","author":"JH Choi","year":"2014","unstructured":"Choi JH, Hwang YP, Kim HG, Khanal T, Do MT, Jin SW, Han HJ, Lee HS, Lee YC, Chung YC, et al. Saponins from the roots of Platycodon grandiflorum suppresses TGFbeta1-induced epithelial-mesenchymal transition via repression of PI3K\/Akt, ERK1\/2 and Smad2\/3 pathway in human lung carcinoma A549 cells. Nutr Cancer. 2014;66(1):140\u201351.","journal-title":"Nutr Cancer"},{"issue":"5","key":"906_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/1535370218754848","volume":"243","author":"P Ma","year":"2018","unstructured":"Ma P, Ni K, Ke J, Zhang W, Feng Y, Mao Q. miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1\/2. Exp Biol Med (Maywood). 2018;243(5):473\u201380.","journal-title":"Exp Biol Med (Maywood)"},{"key":"906_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.biopha.2018.06.025","volume":"105","author":"W Ma","year":"2018","unstructured":"Ma W, Liu B, Li J, Jiang J, Zhou R, Huang L, Li X, He X, Zhou Q. MicroRNA-302c represses epithelial-mesenchymal transition and metastasis by targeting transcription factor AP-4 in colorectal cancer. Biomed Pharmacother. 2018;105:670\u20136.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"906_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3892\/or.2017.5376","volume":"37","author":"X Zhang","year":"2017","unstructured":"Zhang X, Wei C, Li J, Liu J, Qu J. MicroRNA-194 represses glioma cell epithelialtomesenchymal transition by targeting Bmi1. Oncol Rep. 2017;37(3):1593\u2013600.","journal-title":"Oncol Rep"},{"issue":"1","key":"906_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/path.4443","volume":"235","author":"Y Sun","year":"2015","unstructured":"Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015;235(1):25\u201336.","journal-title":"J Pathol"},{"issue":"1","key":"906_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3892\/ijo.2015.3241","volume":"48","author":"H Tan","year":"2016","unstructured":"Tan H, He Q, Gong G, Wang Y, Li J, Wang J, Zhu D, Wu X. miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. Int J Oncol. 2016;48(1):181\u201390.","journal-title":"Int J Oncol"},{"issue":"5","key":"906_CR21","doi-asserted-by":"publisher","first-page":"e96718","DOI":"10.1371\/journal.pone.0096718","volume":"9","author":"X Zhou","year":"2014","unstructured":"Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, Di W, Qiu L. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT\/ERK1\/2 inactivation by targeting EGFR in epithelial ovarian cancer. PLoS One. 2014;9(5):e96718.","journal-title":"PLoS One"},{"issue":"5","key":"906_CR22","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3892\/or.2014.3106","volume":"31","author":"F Guo","year":"2014","unstructured":"Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, Zhang W. MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep. 2014;31(5):2021\u20138.","journal-title":"Oncol Rep"},{"issue":"2","key":"906_CR23","first-page":"34","volume":"7","author":"G Zhao","year":"2015","unstructured":"Zhao G, Guo Y, Chen Z, Wang Y, Yang C, Dudas A, Du Z, Liu W, Zou Y, Szabo E, et al. miR-203 functions as a tumor suppressor by inhibiting epithelial to mesenchymal transition in ovarian Cancer. J Cancer Sci Ther. 2015;7(2):34\u201343.","journal-title":"J Cancer Sci Ther"},{"issue":"55","key":"906_CR24","doi-asserted-by":"crossref","first-page":"94666","DOI":"10.18632\/oncotarget.21863","volume":"8","author":"G Zhao","year":"2017","unstructured":"Zhao G, Wang Q, Gu Q, Qiang W, Wei JJ, Dong P, Watari H, Li W, Yue J. Lentiviral CRISPR\/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells. Oncotarget. 2017;8(55):94666\u201380.","journal-title":"Oncotarget"},{"key":"906_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep19995","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Zhou SY, Yan HZ, Xu DD, Chen HX, Wang XY, Wang X, Liu YT, Zhang L, Wang S, et al. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1. Sci Rep. 2016;6:19995.","journal-title":"Sci Rep"},{"issue":"1","key":"906_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cbf.2863","volume":"31","author":"W Wei","year":"2013","unstructured":"Wei W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z. miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Funct. 2013;31(1):82\u20135.","journal-title":"Cell Biochem Funct"},{"issue":"8","key":"906_CR27","doi-asserted-by":"publisher","first-page":"e105331","DOI":"10.1371\/journal.pone.0105331","volume":"9","author":"Z Chen","year":"2014","unstructured":"Chen Z, Wang Y, Liu W, Zhao G, Lee S, Balogh A, Zou Y, Guo Y, Zhang Z, Gu W, et al. Doxycycline inducible Kruppel-like factor 4 lentiviral vector mediates mesenchymal to epithelial transition in ovarian cancer cells. PLoS One. 2014;9(8):e105331.","journal-title":"PLoS One"},{"issue":"6","key":"906_CR28","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.21873\/anticanres.12618","volume":"38","author":"JS Kim","year":"2018","unstructured":"Kim JS, Choi DW, Kim CS, Yu SK, Kim HJ, Go DS, Lee SA, Moon SM, Kim SG, Chun HS, et al. MicroRNA-203 induces apoptosis by targeting Bmi-1 in YD-38 Oral Cancer cells. Anticancer Res. 2018;38(6):3477\u201385.","journal-title":"Anticancer Res"},{"issue":"10","key":"906_CR29","first-page":"5425","volume":"37","author":"HS Lim","year":"2017","unstructured":"Lim HS, Kim CS, Kim JS, Yu SK, Go DS, Lee SA, Moon SM, Chun HS, Kim SG, Kim DK. Suppression of Oral carcinoma oncogenic activity by microRNA-203 via Down-regulation of SEMA6A. Anticancer Res. 2017;37(10):5425\u201333.","journal-title":"Anticancer Res"},{"key":"906_CR30","doi-asserted-by":"publisher","first-page":"42680","DOI":"10.1038\/srep42680","volume":"7","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Liang H, Liao Z, Wang Y, Hu X, Chen X, Xu L, Hu Z. miR-203 enhances let-7 biogenesis by targeting LIN28B to suppress tumor growth in lung cancer. Sci Rep. 2017;7:42680.","journal-title":"Sci Rep"},{"issue":"12","key":"906_CR31","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1111\/cas.13401","volume":"108","author":"Y Chi","year":"2017","unstructured":"Chi Y, Jin Q, Liu X, Xu L, He X, Shen Y, Zhou Q, Zhang J, Jin M. miR-203 inhibits cell proliferation, invasion, and migration of non-small-cell lung cancer by downregulating RGS17. Cancer Sci. 2017;108(12):2366\u201372.","journal-title":"Cancer Sci"},{"issue":"68","key":"906_CR32","doi-asserted-by":"crossref","first-page":"112980","DOI":"10.18632\/oncotarget.22945","volume":"8","author":"CH Yang","year":"2017","unstructured":"Yang CH, Wang Y, Sims M, Cai C, He P, Hacker H, Yue J, Cheng J, Boop FA, Pfeffer LM. MicroRNA203a suppresses glioma tumorigenesis through an ATM-dependent interferon response pathway. Oncotarget. 2017;8(68):112980\u201391.","journal-title":"Oncotarget"},{"key":"906_CR33","doi-asserted-by":"crossref","unstructured":"Shen J, Zhang J, Xiao M, Yang J, Zhang N. MiR-203 suppresses bladder Cancer cell growth and targets the Twist1. Oncol Res. 2017.","DOI":"10.3727\/096504017X15041934685237"},{"issue":"11","key":"906_CR34","doi-asserted-by":"publisher","first-page":"e0143441","DOI":"10.1371\/journal.pone.0143441","volume":"10","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhang Y, Liu X, Fang A, Li P, Li Z, Liu T, Yang Y, Du L, Wang C. MicroRNA-203 is a prognostic Indicator in bladder Cancer and enhances Chemosensitivity to cisplatin via apoptosis by targeting Bcl-w and Survivin. PLoS One. 2015;10(11):e0143441.","journal-title":"PLoS One"},{"issue":"1","key":"906_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3233\/CBM-160167","volume":"19","author":"P Gao","year":"2017","unstructured":"Gao P, Wang S, Jing F, Zhan J, Wang Y. microRNA-203 suppresses invasion of gastric cancer cells by targeting ERK1\/2\/slug\/ E-cadherin signaling. Cancer Biomark. 2017;19(1):11\u201320.","journal-title":"Cancer Biomark"},{"issue":"8","key":"906_CR36","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/abbs\/gmw063","volume":"48","author":"P Zhou","year":"2016","unstructured":"Zhou P, Jiang N, Zhang GX, Sun Q. MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM. Acta Biochim Biophys Sin Shanghai. 2016;48(8):696\u2013703.","journal-title":"Acta Biochim Biophys Sin Shanghai"},{"key":"906_CR37","doi-asserted-by":"publisher","first-page":"28301","DOI":"10.1038\/srep28301","volume":"6","author":"B Deng","year":"2016","unstructured":"Deng B, Wang B, Fang J, Zhu X, Cao Z, Lin Q, Zhou L, Sun X. MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2. Sci Rep. 2016;6:28301.","journal-title":"Sci Rep"},{"key":"906_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1756-9966-31-58","volume":"31","author":"C Wang","year":"2012","unstructured":"Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"906_CR39","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3892\/etm.2017.4828","volume":"14","author":"J Lin","year":"2017","unstructured":"Lin J, Wang L, Gao J, Zhu S. MiR-203 inhibits estrogen-induced viability, migration and invasion of estrogen receptor alpha-positive breast cancer cells. Exp Ther Med. 2017;14(3):2702\u20138.","journal-title":"Exp Ther Med"},{"key":"906_CR40","doi-asserted-by":"crossref","unstructured":"Liu J, Yang L, Guo X, Jin G, Wang Q, Lv D, Liu J, Chen Q, Song Q, Li B. Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells. Mol Med Rep. 2018.","DOI":"10.3892\/mmr.2018.8949"},{"issue":"8","key":"906_CR41","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/1947601911429743","volume":"2","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z, Dong JT. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast Cancer cells. Genes Cancer. 2011;2(8):782\u201391.","journal-title":"Genes Cancer"},{"issue":"7","key":"906_CR42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1947601911425832","volume":"2","author":"P Ru","year":"2011","unstructured":"Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast Cancer cells and enhances cisplatin Chemosensitivity. Genes Cancer. 2011;2(7):720\u20137.","journal-title":"Genes Cancer"},{"key":"906_CR43","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.2147\/OTT.S108712","volume":"9","author":"S He","year":"2016","unstructured":"He S, Zhang G, Dong H, Ma M, Sun Q. miR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer. Onco Targets Ther. 2016;9:6203\u201310.","journal-title":"Onco Targets Ther"},{"issue":"11","key":"906_CR44","doi-asserted-by":"publisher","first-page":"14989","DOI":"10.1007\/s13277-016-5415-1","volume":"37","author":"Z Xiaohong","year":"2016","unstructured":"Xiaohong Z, Lichun F, Na X, Kejian Z, Xiaolan X, Shaosheng W. MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway. Tumour Biol. 2016;37(11):14989\u201397.","journal-title":"Tumour Biol"},{"issue":"1","key":"906_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10549-014-3238-6","volume":"149","author":"MR Clemens","year":"2015","unstructured":"Clemens MR, Gladkov OA, Gartner E, Vladimirov V, Crown J, Steinberg J, Jie F, Keating A. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2015;149(1):171\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"906_CR46","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/annonc\/mdt249","volume":"24","author":"RJ Kelly","year":"2013","unstructured":"Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et al. A phase I\/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(10):2601\u20136.","journal-title":"Ann Oncol"},{"issue":"4","key":"906_CR47","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/annonc\/mdr353","volume":"23","author":"AW Tolcher","year":"2012","unstructured":"Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012;23(4):968\u201373.","journal-title":"Ann Oncol"},{"issue":"32","key":"906_CR48","doi-asserted-by":"publisher","first-page":"21209","DOI":"10.1074\/jbc.M109.018374","volume":"284","author":"JR Neil","year":"2009","unstructured":"Neil JR, Tian M, Schiemann WP. X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem. 2009;284(32):21209\u201317.","journal-title":"J Biol Chem"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-018-0906-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:24:47Z","timestamp":1589549087000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-018-0906-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0906-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"8 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"235"}}